Abstracts Archive - Page 2141 of 2425 - ACR Meeting Abstracts

Abstract Number: 1653 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Synovial IL-21+CD4+ T Cells Specifically Induce Matrix Metalloproteinase Production By Fibroblast-Like Synoviocytes
Maria C. Lebre¹, Pedro L. Vieira², Saïda Aarrass¹, Thomas Newsom-Davis², Paul Peter Tak³ and Gavin R. Screaton², ¹Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Immunology, Imperial College London, London, United Kingdom, ³Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: IL-21 is a cytokine produced by activated CD4+ T cells and T follicular helper cells (TFh) that has been implicated in several autoimmune diseases…
Abstract Number: 1654 • 2013 ACR/ARHP Annual Meeting
Characterization Of T Cell Phenotype and Function In a Double Transgenic (Collagen-Specific TCR /HLA-DR1) Humanized Model Of Arthritis
Seunghyun Kim¹, Bo Tang², Sarah Hammond³, DL Cullins³, David Brand⁴, EF Rosloniec³, John M. Stuart⁵, Arnold E. Postlethwaite⁶, AH Kang³ and Linda Myers³, ¹Medicine/Rheumatology, University of Tennessee Health Science Center, Memphis, TN, ²Immunology, St. Jude Children's Research Hospital, Memphis, TN, ³University of Tennessee Health Science Center, Memphis, TN, ⁴Research Service 151, VA Medical Center, Memphis, TN, ⁵Medicine, VA Medical Center, University of Tennessee Health Science Center, Memphis, TN, ⁶Med-Div of Conn Tis Dis, University of Tennessee Health Science Center, Memphis, TN
Background/Purpose: T cells orchestrate joint inflammation in rheumatoid arthritis (RA), yet they are difficult to study due to the small numbers of antigen-specific cells. The…
Abstract Number: 1655 • 2013 ACR/ARHP Annual Meeting
HLA-B27 and KIR3DL2 Interactions Promote The Differentiation and Survival Of Proinflammatory T Cells In Spondyloarthritis
A. Ridley¹, I. Wong-Baeza², H. Hatano², J. Shaw², H. Al-Mossawi², P. Bowness² and S. Kollnberger², ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: T helper 17 (Th17) cells are a subset of pro-inflammatory CD4+ T cells implicated in a number of inflammatory arthritides including the Spondyloarthritides (SpAs). …
Abstract Number: 1656 • 2013 ACR/ARHP Annual Meeting
Interferon Type I and T Helper 17: A Dangerous Liaison In Primary Sjögren’s Syndrome?
Zana Brkic¹, Sandra M.J. Paulissen², Cornelia G. van Helden-Meeuwsen³, Naomi I. Maria³, Odilia B.J. Corneth⁴, Nadine Davelaar⁵, Jan Piet van Hamburg⁵, Paul L. Van Daele³, Virgil A. Dalm¹, Martin van Hagen³, Erik Lubberts⁶ and Marjan A. Versnel¹, ¹Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ²Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology and Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁵Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: The T helper 17 (Th17) cell subset, which produces IL-17A, IL-17F, IL-22 and IL-21, has been implicated in the pathogenesis of primary Sjögren’s syndrome…
Abstract Number: 1657 • 2013 ACR/ARHP Annual Meeting
Enothelin-1 Plays a Role In The Pathogenesis Of Reversible Cerebral Vasoconstriction Syndrome
Tariq Hammad¹, Leonard H. Calabrese², Ken Uchino³, Seby John³, Mark Stillman⁴, Stewart Tepper⁴, Colin O'Rourke⁵, Allison Janocha¹, Serpil Erzurum¹ and Rula Hajj-Ali⁴, ¹Cleveland Clinic, Cleveland, OH, ²Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ³Neurology, Cleveland Clinic Foundation, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH, ⁵Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
Background/Purpose: Cerebral vasoconstriction is thought to be the underlying pathogenetic mechanism of Reversible Cerebral Vasoconstriction Syndromes (RCVS). However, mediators of the syndrome at molecular levels…
Abstract Number: 1658 • 2013 ACR/ARHP Annual Meeting
Vessel Wall Characteristics Using High Resolution Magnetic Resonance Imaging In Reversible Cerebral Vasoconstriction Syndrome and Central Nervous System vasculitis
Rula Hajj-Ali¹, Seby John², Tariq Hammad³, Emmanuel Obusez³, Ken Uchino², Stephen Jones⁴, Ferdinand Hui⁵, Russell Cerejo³ and Leonard H. Calabrese⁶, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Neurology, Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH, ⁴Neuroradiology, Cleveland Clinic, Cleveland, OH, ⁵Cerebrovascular, Clevalnd Clinic, Cleveland, OH, ⁶Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH
Background/Purpose: Distinguishing between reversible cerebral vasoconstriction syndrome (RCVS) and central nervous system (CNS) vasculitis is often a diagnostic dilemma. High-resolution-3-Tesla Magnetic Resonance Imaging with contrast…
Abstract Number: 1660 • 2013 ACR/ARHP Annual Meeting
Primary Central Nervous System Vasculitis: Treatment and Course
Carlo Salvarani¹, Robert D. Brown Jr.², Teresa J. H. Christianson², John Huston III², Kenneth Calamia³, Caterina Giannini² and Gene G. Hunder⁴, ¹Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Jacksonville, FL, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: To determine the response to therapy and long-term outcome of PCNSV we reviewed all cases of PCNSV seen over a 29-year period. Methods:…
Abstract Number: 1661 • 2013 ACR/ARHP Annual Meeting
The Spectrum of childhood Inflammatory Brain Diseases; An Increasingly Recognised Field
Marinka Twilt¹, Eyal Muscal², Tania Cellucci³, Pavla Dolezalova⁴, Rob Forsyth⁵, Susan Kim⁶, David A. Cabral⁷, Johannes Roth⁸, Adam Kirton⁹, Rolando Cimaz¹⁰, Jasmin Kummerle-Deschner¹¹, Annet van Royen-Kerkhof¹², Jürgen Brunner¹³, Gaelle Chedeville¹⁴, Jordi Anton¹⁵, Angela Robinson¹⁶, Mary Toth¹⁷, Tilmann Kallinich¹⁸, Claudia Bracaglia¹⁹, Alexis Boneparth²⁰, Shehla Sheikh²¹ and Susanne M. Benseler²¹, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²TCH Pediatric Rheum Center, Baylor College of Medicine, Houston, TX, ³Rheumatology, Hamilton Health Sciences, McMaster, Hamilton, ON, Canada, ⁴Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ⁵Newcastle upon Tyne's NHS foundation Trust, Newcastle upon Tyne, United Kingdom, ⁶Division of Immunology, Boston Children's Hospital, Boston, MA, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸University of Ottawa, Ottawa, ON, Canada, ⁹Neurology, Alberta Children's Hospital, Calgary, AB, Canada, ¹⁰Rheumatology Unit, A. Meyer Children's Hospital, Florence, Italy, ¹¹University Childrens Clinic Tuebingen, Tuebingen, Germany, ¹²Department of Pediatric Immunology & Rheumatology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands, ¹³pediatric Rheumatology, University Children's Hospital, Innsbruck, Austria, ¹⁴Pediatric Rheumatology, Montreal Children's Hospital, Montreal, QC, Canada, ¹⁵Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ¹⁶Pediatrics, Rainbow Babies & Children's Hospital / Case Medical Center, Cleveland, OH, ¹⁷Rheumatology, Akron Children's Hospital, Akron, OH, ¹⁸Charite, University Medicine Berlin, Berlin, Germany, ¹⁹Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²⁰Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²¹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Childhood Inflammatory Brain diseases are potentially life-threatening diseases leading to severe neurological deficits if not treated. The spectrum of childhood inflammatory brain diseases is…
Abstract Number: 1662 • 2013 ACR/ARHP Annual Meeting
Developing Guideline For Polymyalgia Rheumatica: Prioritisation Of Outcome Measures – Perspective Of Patients, General Practitioners and Rheumatologists
Yogesh Singh¹, Christian Dejaco^2,3, Sarah Mackie⁴, Daniel Ching⁵, Artur Bachta⁶, Ajesh Maharaj⁷, Alexandre Wagner⁸, Manuela Lima⁹, David Jayne¹⁰, Kevin Barraclough¹¹, Christian D Mallen¹², Stephen P. Merry¹³, Jane Hollywood¹⁴, Madeline Whitlock¹⁵, Kate Gilbert¹⁶, Pamela Hildreth¹⁶, Jennifer Nott¹⁶, Hannah Padbury¹⁶, Jean Miller¹⁶, Lorna Neill¹⁶, David Tronnier¹⁷, Pablo Perel¹⁸, Andrew Hutchings¹⁹, Dario Camellino²⁰, Steven E. Carsons²¹, William Docken²², Christina Duftner²³, Andy Abril²⁴, Robert F. Spiera²⁵, Colin T. Pease²⁶, Andreas P. Diamantopoulos²⁷, Frank Buttgereit²⁸, Peter V. Balint²⁹, Elisabeth Nordborg³⁰, Lina Bianconi³¹, Billy Fashanu¹⁵, Shunsuke Mori³², Víctor M. Martínez-Taboada³³, Maria C. Cid³⁴, Wolfgang A. Schmidt³⁵, Marco A. Cimmino³⁶, Michael Schirmer³⁷, Carlo Salvarani³⁸, Eric L. Matteson³⁹ and Bhaskar Dasgupta⁴⁰, ¹Rheumatology, Southend university hospital, Westcliff-on-sea, United Kingdom, ²Rheumatology and Immunology, Medical University Graz, Graz, Austria, ³Department of Rheumatology and Immunology, Medical University Graz, Graz A-8036, Austria, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁵Timaru Hospital, Timaru, New Zealand, ⁶Military Medical Institute, Warsaw, Poland, ⁷Prince Mshiyeni Memorial Hospital, Durban, South Africa, ⁸Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁹Universidade dos Açores, Azores, Portugal, ¹⁰Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ¹¹Hoyland House General Practice, Painswick, United Kingdom, ¹²Arthritis Research UK Primary Care Centre, University of Keele, Keele, United Kingdom, ¹³Family Medicine, Mayo Clinic, Rochester, MN, ¹⁴Rheumatology, Southend Hospital, Southend, United Kingdom, ¹⁵Southend University Hospital, Southend, United Kingdom, ¹⁶PMRGCAUK, Southend, United Kingdom, ¹⁷patients' representative, Rochester, MN, ¹⁸London School of Hygiene & Tropical Medicine, London, United Kingdom, ¹⁹Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ²⁰Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy, ²¹Div of Rheumatology, Winthrop University Hospital, Mineola, NY, ²²Brigham Orth & Arthritis Center, Chestnut Hill, MA, ²³Internal Medicine, Hopital Kufstein, Kufstein, Austria, ²⁴Rheumatology, Mayo Clinic Florida, Jacksonville, FL, ²⁵Rheumatology, Hospital for Special Surgery, New York, NY, ²⁶Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²⁷Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²⁸Charité - Universitätsmedizin Berlin, Berlin, Germany, ²⁹Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ³⁰Sahlgenska University Hospital, Goteborg, Sweden, ³¹Ambulatorio Medicina Generale, Bibbiano, Italy, ³²Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan, ³³Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, ³⁴Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Med Ctr Rheumatology Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³⁷Internal medicine, Innsbruck Medical University, Innsbruck, Austria, ³⁸Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ³⁹Rheumatology, Mayo Clinic, Rochester, MN, ⁴⁰Southend University Hospital, Essex, United Kingdom
Background/Purpose: To explore similarities and differences between rheumatologists (rheum), general practitioners (GP) and patients (pt) regarding the relevance of outcome parameters in polymyalgia rheumatica (PMR).Methods:…
Abstract Number: 1663 • 2013 ACR/ARHP Annual Meeting
Obese Polymyalgia Rheumatica Patients Experience More Pain and Disability and Need Higher Doses Of Glucocorticoids
Marco A. Cimmino¹, Bhaskar Dasgupta², Cynthia S. Crowson³, Michael Schirmer⁴, Christian Dejaco⁵, Carlo Salvarani⁶ and Eric L. Matteson⁷, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Internal medicine, Innsbruck Medical University, Innsbruck, Austria, ⁵Department of Rheumatology and Immunology, Medical University Graz, Graz A-8036, Austria, ⁶Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁷Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Obesity is not only a risk factor for osteoarthritis but also for rheumatoid arthritis (RA). In obese RA patients, disease incidence is higher and…
Abstract Number: 1664 • 2013 ACR/ARHP Annual Meeting
Lower Tissue Expression Of IL 6 In Patients With Giant Cell Arteritis Presenting With a Cranial Ischaemic Compication
Lorraine O'Neill¹, Jennifer McCormick², Danielle Molloy¹, Douglas J. Veale¹, Conor Murphy³, Geraldine M. McCarthy⁴, Ursula Fearon² and Eamonn S. Molloy¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ²Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ³Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁴Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland
Background/Purpose: Giant Cell Arteritis (GCA) is a granulomatous systemic vasculitis with a prediliction for the aorta and it’s extracranial branches. The majority of the morbidity…
Abstract Number: 1623 • 2013 ACR/ARHP Annual Meeting
Differential Methylation Of Interferon-Related Genes Is Associated With Anti-dsDNA Autoantibody Production In Systemic Lupus Erythematosus
Sharon A. Chung¹, Joanne Nititham², Kimberly E. Taylor¹, Emon Elboudwarej³, Hong L. Quach³, Lisa F. Barcellos³ and Lindsey A. Criswell², ¹University of California, San Francisco, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ³Epidemiology, University of California, Berkeley, Berkeley, CA
Background/Purpose: DNA methylation studies in systemic lupus erythematosus (SLE) have shown that SLE patients have less methylation in genes regulating the immune response compared to…
Abstract Number: 1624 • 2013 ACR/ARHP Annual Meeting
Lupus Risk Alleles With High Ethnic Variability Worldwide Are Associated With Renal Disease In Hispanic Patients
Belinda Waltman¹, Kimberly E. Taylor², Joanne Nititham³ and Lindsey A. Criswell³, ¹Department of Medicine, University of California, San Francisco, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects minority patients. Non-European ancestry is associated with more severe disease, and conversely, European ancestry is associated with a…
Abstract Number: 1625 • 2013 ACR/ARHP Annual Meeting
Prolactin-Induced Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation In Monomac-6 Cells Correlating With Changes Seen In Monocytes From Systemic Lupus Erythematosus Patients
Yiu Tak Leung¹, Lihua Shi², Kelly Maurer², Li Song², Michelle Petri³ and Kate Sullivan⁴, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Epigenetic changes have been described in systemic lupus erythematosus (SLE) and offer a potential explanation for the chronicity of disease and missing heritability. Therapies…
Abstract Number: 1626 • 2013 ACR/ARHP Annual Meeting
Genetic Alterations In Abnormal Neutrophils Isolated From Human Systemic Lupus Erythematosus Patients
Namrata Singh¹, Kayla Martin², Mariana J. Kaplan³, Philip L. Cohen⁴ and Michael F. Denny⁵, ¹Internal Medicine, Temple University, Philadelphia, PA, ²Microbiology and Immunology, Temple University, Philadelphia, PA, ³Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD, ⁴Rheumatology, Temple University School of Medicine, Philadelphia, PA, ⁵Rheumatology, Temple University, Philadelphia, PA
Background/Purpose: Human SLE patients have an abnormal population of neutrophils called low density granulocytes (LDGs). LDGs express the surface markers of mature neutrophils, yet their…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].